On December 23, 2022, at the "2022 China Potential Unicorn Report Launch" jointly organized by Great Wall Institute of Strategic Consulting (GEI) and Suzhou Industrial Park Administrative Committee, GEI unveiled 595 selected companies in 39 tracks, among which Mobidrop Bio was listed in the " In vitro diagnostics" track, becoming a new potential unicorn in GEI China.

According to the 2022 China Potential Unicorn Research Report, the overall number of potential unicorns in China in 2021 was 595, an increase of 170 companies year -on-year, with a growth rate of 40.0%; among them, 359 were newcomers, with a year-on-year growth rate of 44.8%. Potential unicorns are located in 21 provinces and 50 cities, with a total of 418 companies in the "North, Shanghai, Suzhou, Shenzhen and Hangzhou", accounting for 70.3% of the total number of potential unicorns in China. Nearly 70% of the potential unicorns are located in national high-tech zones, with Zhongguancun in Beijing, Zhangjiang in Shanghai, Suzhou Industrial Park, Shenzhen High-tech Zone and Nanjing High-tech Zone ranking among the top five. Among them, six tracks, including innovative pharmaceuticals, integrated circuits, enterprise digital operations, artificial intelligence, in vitro diagnostics, and innovative medical devices, gathered nearly 50% of China's potential unicorns.

Potential unicorns in China are playing an increasingly important role in leading new tracks, promoting high-quality regional economic development, and facilitating the transformation of old and new dynamics. On the one hand, potential unicorns have gold standards for registration qualification and financing scale, and on the other hand, potential unicorns are growth-oriented innovative enterprises, the most sunrise and technology-driven enterprises in the industry sector, rich in frontier and disruption in their own genes.

Mobidrop Bio will continue to develop its own one-stop solution for high-throughput single-cell multi-omics  sequencing of animal, plant and microbial samples based on innovative microfluidic technology, enabling a wide range of life sciences and precision medicine.

GEI China Potential Unicorn Enterprise Criteria:

(1) registered in the territory of China, with legal personality of the enterprise;

(2) Meet one of the following conditions: $100 million post -investment valuation for the last round of financing within 5 years of establishment; $500 million post -investment valuation for the last round of financing between 5 and 9 years of establishment;

(3) Have received private investment and have not yet gone public.

About Mobidrop

Founded in Boston, USA, and located in Zhejiang, China, Mobidrop Bio is a group of talented individuals consisting of top international scientists and executives from multinational medical device companies. Mobidrop is committed to empowering scientific research and precision medicine with innovative microfluidics and single-cell sequencing  technologies. It has become a leader in research+IVD solutions with key technologies such as microfluidics, sequencing, biochemistry, hardware development, and bioconferencing, and has launched a dual technology platform for single-cell sequencing and digital PCR, developing in parallel in multiple fields such as liquid biopsy, companion diagnostics, and life science research.